Clinical outcomes and anti-inflammatory mechanisms of nucleus basalis of Meynert deep brain stimulation in Alzheimer's disease.

IF 2.8 3区医学 Q2 CLINICAL NEUROLOGY

Frontiers in Neurology Pub Date : 2026-04-22 eCollection Date: 2026-01-01 DOI:10.3389/fneur.2026.1773910

Yingchuan Chen, Tingting Du, Tenghong Lian, Yin Jiang, Tianshuo Yuan, Jing Li, Fangang Meng, Anchao Yang, Wei Zhang, Jianguo Zhang

{"title":"Clinical outcomes and anti-inflammatory mechanisms of nucleus basalis of Meynert deep brain stimulation in Alzheimer's disease.","authors":"Yingchuan Chen, Tingting Du, Tenghong Lian, Yin Jiang, Tianshuo Yuan, Jing Li, Fangang Meng, Anchao Yang, Wei Zhang, Jianguo Zhang","doi":"10.3389/fneur.2026.1773910","DOIUrl":null,"url":null,"abstract":"Aim: Deep brain stimulation of the nucleus basalis of Meynert (NBM-DBS) represents an emerging therapeutic strategy for Alzheimer's disease (AD), yet clinical outcomes have been inconsistent and its mechanistic underpinnings are not fully elucidated. This study aimed to assess the cognitive and psychobehavioral effects of NBM-DBS and to explore its potential impact on systemic inflammatory markers.Methods: In this open-label trial, nine individuals with moderate-to-severe AD underwent bilateral NBM-DBS. Six participants (four with moderate and two with severe AD) completed the full 12-month protocol, which included serial neuropsychiatric assessments and serum cytokine profiling.Results: Stratification by baseline disease severity revealed divergent cognitive trajectories. Patients with moderate AD (CDR = 2) maintained their preoperative performance on the Montreal Cognitive Assessment (MoCA) and Boston Naming Test (BNT) over the 12-month follow-up. In contrast, patients with severe AD (CDR = 3) experienced significant decline on these measures. Serum analyses demonstrated a significant immunomodulatory effect, characterized by elevated levels of the anti-inflammatory cytokines IL-10 and IL-27, and reduced levels of the pro-inflammatory chemokines CXCL10 and RANTES at the 12-month timepoint.Conclusion: Our findings indicate that NBM-DBS may be associated with stabilization of cognitive function in patients with moderate AD, potentially through the modulation of inflammation. The therapeutic benefit appears to be more pronounced in the moderate stage of the disease.","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"17 ","pages":"1773910"},"PeriodicalIF":2.8000,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143682/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fneur.2026.1773910","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Deep brain stimulation of the nucleus basalis of Meynert (NBM-DBS) represents an emerging therapeutic strategy for Alzheimer's disease (AD), yet clinical outcomes have been inconsistent and its mechanistic underpinnings are not fully elucidated. This study aimed to assess the cognitive and psychobehavioral effects of NBM-DBS and to explore its potential impact on systemic inflammatory markers.

Methods: In this open-label trial, nine individuals with moderate-to-severe AD underwent bilateral NBM-DBS. Six participants (four with moderate and two with severe AD) completed the full 12-month protocol, which included serial neuropsychiatric assessments and serum cytokine profiling.

Results: Stratification by baseline disease severity revealed divergent cognitive trajectories. Patients with moderate AD (CDR = 2) maintained their preoperative performance on the Montreal Cognitive Assessment (MoCA) and Boston Naming Test (BNT) over the 12-month follow-up. In contrast, patients with severe AD (CDR = 3) experienced significant decline on these measures. Serum analyses demonstrated a significant immunomodulatory effect, characterized by elevated levels of the anti-inflammatory cytokines IL-10 and IL-27, and reduced levels of the pro-inflammatory chemokines CXCL10 and RANTES at the 12-month timepoint.

Conclusion: Our findings indicate that NBM-DBS may be associated with stabilization of cognitive function in patients with moderate AD, potentially through the modulation of inflammation. The therapeutic benefit appears to be more pronounced in the moderate stage of the disease.

查看原文本刊更多论文

Meynert脑深部刺激基底核治疗阿尔茨海默病的临床疗效及抗炎机制

目的：脑深部刺激Meynert基底核（NBM-DBS）是阿尔茨海默病（AD）的一种新兴治疗策略，但临床结果不一致，其机制基础尚未完全阐明。本研究旨在评估NBM-DBS对认知和心理行为的影响，并探讨其对全身炎症标志物的潜在影响。方法：在这项开放标签试验中，9名中重度AD患者接受了双侧NBM-DBS治疗。6名参与者（4名中度阿尔茨海默病患者和2名重度阿尔茨海默病患者）完成了为期12个月的完整治疗方案，其中包括一系列神经精神评估和血清细胞因子分析。结果：基线疾病严重程度分层揭示了不同的认知轨迹。中度AD患者（CDR = 2）在12个月的随访中，蒙特利尔认知评估（MoCA）和波士顿命名测试（BNT）的术前表现保持正常。相比之下，严重AD患者（CDR = 3）在这些指标上有显著下降。血清分析显示了显著的免疫调节作用，其特征是在12个月的时间点上，抗炎细胞因子IL-10和IL-27水平升高，促炎趋化因子CXCL10和RANTES水平降低。结论：我们的研究结果表明，NBM-DBS可能与中度AD患者认知功能的稳定有关，可能通过调节炎症。这种治疗效果在疾病的中度阶段更为明显。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Neurology CLINICAL NEUROLOGYNEUROSCIENCES -NEUROSCIENCES

CiteScore

4.90

自引率

8.80%

发文量

2792

审稿时长

14 weeks

期刊介绍： The section Stroke aims to quickly and accurately publish important experimental, translational and clinical studies, and reviews that contribute to the knowledge of stroke, its causes, manifestations, diagnosis, and management.